Literature DB >> 24590821

Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy.

A Mukhopadhyay1, S Dasgupta, U Kanti Ray, F Gharami, C K Bose, S Mukhopadhyay.   

Abstract

INTRODUCTION: Imatinib is a first-line therapy to treat chronic myeloid leukemia (CML) patients.
MATERIALS AND METHODS: We selected 22 CML cases of pregnancies and reported 9 accidental and 13 planned pregnancies that were on imatinib therapy. Willing female patients remaining in complete hematological, cytogenetic and major molecular responses for at least 2 years planned for pregnancy and were advised to stop imatinib for 1 month prior to conception and 3 months after conception (first trimester). Willing male patients stopped therapy 1 month prior to conception of their wives. In unplanned cases, all patients were in exposure to imatinib during conception. Twenty-two pregnancies resulted in seven male children and eight female children. There were three spontaneous abortions and four elective abortions along with one case of hypospadia and another one of mild hydrocephalus.
CONCLUSION: We may suggest that planned pregnancy during therapy may be encouraged but imatinib therapy in unplanned pregnancy can cause spontaneous abortion or congenital anomaly.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24590821     DOI: 10.1007/s11845-014-1084-5

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  22 in total

1.  Imatinib and pregnancy.

Authors:  Ridvan Ali; Fahir Ozkalemkas; Tulay Ozcelik; Vildan Ozkocaman; Atilla Ozkan
Journal:  J Clin Oncol       Date:  2006-08-10       Impact factor: 44.544

2.  Risk factors for spontaneous abortion and its recurrence.

Authors:  H A Risch; N S Weiss; E A Clarke; A B Miller
Journal:  Am J Epidemiol       Date:  1988-08       Impact factor: 4.897

3.  Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk.

Authors:  M A Russell; M W Carpenter; M S Akhtar; T F Lagattuta; M J Egorin
Journal:  J Perinatol       Date:  2007-04       Impact factor: 2.521

4.  Imatinib has deleterious effects on differentiating spermatogonia while sparing spermatogonial stem cell self renewal.

Authors:  Crystal Heim; Kayla Minniear; Christina Tenenhaus Dann
Journal:  Reprod Toxicol       Date:  2011-02-01       Impact factor: 3.143

Review 5.  Imatinib treatment: specific issues related to safety, fertility, and pregnancy.

Authors:  Martee L Hensley; John M Ford
Journal:  Semin Hematol       Date:  2003-04       Impact factor: 3.851

Review 6.  Imatinib and beyond--exploring the full potential of targeted therapy for CML.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes
Journal:  Nat Rev Clin Oncol       Date:  2009-08-04       Impact factor: 66.675

7.  Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: an experience from eastern India.

Authors:  A Mukhopadhyay; S Dasgupta; S Mukhopadhyay; C K Bose; S Sarkar; F Gharami; S Koner; J Basak; U K Roy
Journal:  Indian J Hematol Blood Transfus       Date:  2011-09-21       Impact factor: 0.900

8.  Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.

Authors:  Hagop M Kantarjian; Jorge E Cortes; Susan O'Brien; Francis Giles; Guillermo Garcia-Manero; Stefan Faderl; Deborah Thomas; Sima Jeha; Mary Beth Rios; Laurie Letvak; Kathy Bochinski; Ralph Arlinghaus; Moshe Talpaz
Journal:  Blood       Date:  2002-08-29       Impact factor: 22.113

Review 9.  Leukaemia and pregnancy.

Authors:  M F Fey; D Surbek
Journal:  Recent Results Cancer Res       Date:  2008

Review 10.  First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.

Authors:  Guoqing Wei; Shamudheen Rafiyath; Delong Liu
Journal:  J Hematol Oncol       Date:  2010-11-26       Impact factor: 17.388

View more
  9 in total

Review 1.  [Dermatological topical and systemic therapy during pregnancy].

Authors:  S Grunewald; P Staubach
Journal:  Hautarzt       Date:  2017-02       Impact factor: 0.751

2.  Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase.

Authors:  Xiaohui Chang; Lin Zhou; Xiaoxia Chen; Baoli Xu; Yubin Cheng; Shujun Sun; Meiyun Fang; Yang Xiang
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

3.  Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells.

Authors:  L Charaf; F-X Mahon; I Lamrissi-Garcia; I Moranvillier; F Beliveau; B Cardinaud; S Dabernat; H de Verneuil; F Moreau-Gaudry; A Bedel
Journal:  Leukemia       Date:  2016-05-25       Impact factor: 11.528

Review 4.  Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review.

Authors:  Anupama Rambhatla; Michael R Strug; Jessica Garcia De Paredes; Marcos I Cordoba Munoz; Mili Thakur
Journal:  J Assist Reprod Genet       Date:  2021-04-07       Impact factor: 3.357

5.  Chronic Myeloid Leukemia and Cesarean Section: The Anesthesiologist's Point of View.

Authors:  Houssam Rebahi; Mourad Ait Sliman; Ahmed-Rhassane El Adib
Journal:  Case Rep Obstet Gynecol       Date:  2018-09-18

6.  Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center.

Authors:  Ariella Cássia de Moura; Márcia Torresan Delamain; Gislaine Borba Oliveira Duarte; Irene Lorand-Metze; Cármino Antônio de Souza; Kátia Borgia Barbosa Pagnano
Journal:  Hematol Transfus Cell Ther       Date:  2019-02-18

7.  Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A systematic review.

Authors:  Zsolt Szakács; Péter Jenő Hegyi; Nelli Farkas; Péter Hegyi; Márta Balaskó; Adrienn Erős; Szabina Szujó; Judit Pammer; Bernadett Mosdósi; Mária Simon; Arnold Nagy; Gabriella Für; Alizadeh Hussain
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

8.  Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors.

Authors:  Kong Jun; Qin Ya-Zhen; Zhao Xiao-Su; Shi Hong-Xia; Lai Yue-Yun; Liu Kai-Yan; Huang Xiao-Jun; Jiang Hao
Journal:  Ther Adv Hematol       Date:  2021-01-22

9.  Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review.

Authors:  Dan Ran Castillo; Daniel Park; Akhil Mehta; Simmer Kaur; Anthony Nguyen; Mojtaba Akhtari
Journal:  Hematol Rep       Date:  2022-03-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.